New hope for young leukemia patients: targeted chemo combo aims to boost treatment completion
NCT ID NCT07227584
First seen Nov 12, 2025 · Last updated Apr 30, 2026 · Updated 13 times
Summary
This study is for adolescents and young adults (ages not specified) newly diagnosed with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). Researchers are testing a chemotherapy regimen that includes the immunotherapy drug blinatumomab along with several standard chemo drugs. The main goal is to see how many participants can complete the full treatment plan without stopping early. The study is not yet recruiting and is in Phase 2.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.